LYON, France, Jun 29, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Maple Leaf HIFU, the exclusive distributor of Ablatherm HIFU in Canada, is installing an Ablatherm device at their new medical office located at Cleveland Clinic Canada in Toronto. Patients with localized prostate cancer are now able to benefit from this minimally invasive HIFU procedure.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "I am very pleased that Ablatherm HIFU technology is now available at this location. This move supports our commitment to offer the Ablatherm HIFU solution to a greater number of patients in North America."

Dr. William Orovan, Maple Leaf HIFU's President and Medical Director, added, "Since inception, our mission has been to provide patients throughout North America with access to the latest proven treatment option available for localized prostate cancer: Ablatherm(R) High Intensity Focused Ultrasound. Our clinic strives to be at the forefront of new and effective treatment technology with the potential to provide greater efficacy, fewer side effects, and better quality of life for patients and their families."

Dr. Orovan continued, "Maple Leaf HIFU is proud to be operating within the Canadian office of Cleveland Clinic. We have always focused on providing the best possible care for our patients, and we believe that our new location will assist us in achieving this goal."

Prostate cancer patients interested in being treated by Maple Leaf HIFU are advised to contact them at (877) 370-4438 or by visiting www.hifu.ca.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, http://www.hifu-planet.com.

About Maple Leaf HIFU

Maple Leaf HIFU provides patients throughout North America with access to the latest proven treatment option available for localized prostate cancer: Ablatherm(R) High Intensity Focused Ultrasound. Maple Leaf HIFU first started treating patients in Toronto in 2005. Since that time more than 500 patients have been treated at the clinic using Ablatherm HIFU, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS SA

CONTACT:  EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
Stephanie Carrington
646-536-7017
scarrington@theruthgroup.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX